Results 91 to 100 of about 1,753 (162)

Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology. [PDF]

Dermatol Ther (Heidelb)
Augustin M, Hong HC, Torres T, Issa NT.
europepmc   +1 more source

Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis. [PDF]

Intractable Rare Dis Res
Tanaka H, Ishii T.
europepmc   +1 more source

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis. [PDF]

J Comp Eff Res
Grindley R, Houde L, Sawad AB, Balu S, Schneider S.   +4 more
europepmc   +1 more source

The Effect of Lebrikizumab on Inflammatory Biomarkers in Patients with Asthma

US Respiratory & Pulmonary Diseases, 2023
openaire   +1 more source

Therapy-associated facial redness in atopic dermatitis: insights from a case series. [PDF]

An Bras Dermatol
Sabas-Ortega K, García-González S, Ara-Martín M, Morales-Moya AL, de la Fuente Meira S, Bularca E, Villagrasa-Boli P, Martinez-Lostao L, Rivera-Fuertes I, Prieto-Torres L.   +9 more
europepmc   +1 more source

Treatment of juvenile bullous pemphigoid with lebrikizumab

JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Marcel Wittenberg, Farzan Solimani, Amrei Dilling, Rawan Snobar, Kamran Ghoreschi, Marisa Klemp, Kerstin Kusch   +6 more
openaire   +2 more sources

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'". [PDF]

Dermatol Ther (Heidelb)
Augustin M, Armstrong AW, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T.   +6 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement. [PDF]

Dermatol Ther (Heidelb)
Gargiulo L, Ibba L, Bianco M, Di Giulio S, Valenti M, Avallone G, Zussino M, Calzari P, Marzano AV, Costanzo A, Ferrucci SM, Narcisi A.   +11 more
europepmc   +1 more source

Efficacy and Safety of Lebrikizumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Lopez-Mallama OM, Sandoval-Ato R, Vega PR, Keita H, Diaz-Gonzales G, Rivera-Lozada O, Barboza JJ.   +6 more
europepmc   +1 more source

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation. [PDF]

Allergol Select
Werfel T, Heratizadeh A, Augustin M, Bangert C, Bauer A, Biedermann T, Brans R, Domröse N, Gieler U, Gießler-Fichtner O, Hamelmann E, Hampe S, Heuer R, Kahle J, Kinberger M, Koch M, Köhler M, Legat F, Nemat K, Neustädter I, Peters EMJ, Radonjic-Hoesli S, Reese I, Schmid-Grendelmeier P, Schmidt-Göhrich UK, Schmitt J, Schnopp C, Schwennesen T, Simon D, Stamos K, Termeer C, Treudler R, von Kiedrowski R, Wagner I, Waßmann-Otto A, Weckmann G, Werner RN, Wollenberg A, Worm M, Ott H.   +39 more
europepmc   +1 more source